Skip to main content
Article thumbnail
Location of Repository

The Use of Whole Genome Amplification to Study Chromosomal Changes in Prostate Cancer: Insights into Genome-Wide Signature of Preneoplasia Associated with Cancer Progression

By S Hughes, M Yoshimoto, B Beheshti, R S Houlston, J A Squire and A Evans


<p>Background: Prostate cancer (CaP) is a disease with multifactorial etiology that includes both genetic and environmental components. The knowledge of the genetic basis of CaP has increased over the past years, mainly in the pathways that underlie tumourigenesis, progression and drug resistance. The vast majority of cases of CaP are adenocarcinomas that likely develop through a pre-malignant lesion and high-grade prostatic intraepithelial neoplasia (HPIN). Histologically, CaP is a heterogeneous disease consisting of multiple, discrete foci of invasive carcinoma and HPIN that are commonly interspersed with benign glands and stroma. This admixture with benign tissue can complicate genomic analyses in CaP. Specifically, when DNA is bulk- extracted the genetic information obtained represents an average for all of the cells within the sample. Results: To minimize this problem, we obtained DNA from individual foci of HPIN and CaP by laser capture microdissection ( LCM). The small quantities of DNA thus obtained were then amplified by means of multiple-displacement amplification (MDA), for use in genomic DNA array comparative genomic hybridisation (gaCGH). Recurrent chromosome copy number abnormalities (CNAs) were observed in both HPIN and CaP. In HPIN, chromosomal imbalances involving chromosome 8 where common, whilst in CaP additional chromosomal changes involving chromosomes 6, 10, 13 and 16 where also frequently observed. Conclusion: An overall increase in chromosomal changes was seen in CaP compared to HPIN, suggesting a universal breakdown in chromosomal stability. The accumulation of CNAs, which occurs during this process is non- random and may indicate chromosomal regions important in tumourigenesis. It is therefore likely that the alterations in copy number are part of a programmed cycle of events that promote tumour development, progression and survival. The combination of LCM, MDA and gaCGH is ideally suited for the identification of CNAs from small cell clusters and may assist in the discovery of potential genomic markers for early diagnosis, or identify the location of tumour suppressor genes (TSG) or oncogenes previously unreported in HPIN and CaP.</p

Year: 2006
DOI identifier: 10.1186/1471-2164-7-65
OAI identifier:

Suggested articles


  1. (2004). A: Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate doi
  2. (2001). Camara-Lopes LH: Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol doi
  3. (2005). Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
  4. (2004). Collins C: Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer
  5. (2004). Cornelisse CJ: Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer
  6. (2003). CS: Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene
  7. (2003). DH: Myc confers androgen-independent prostate cancer cell growth. doi
  8. (2004). DJ: Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. doi
  9. (2004). E: Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. Genome Res
  10. (2003). Ekman P: Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate
  11. (2001). Frierson HFJ: Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate
  12. (2004). Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol
  13. (2005). Houlston RS: Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3.
  14. (2000). Identification of genetic markers for prostatic cancer progression. Lab Invest
  15. (2003). Inoue S: EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. doi
  16. (1999). JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet
  17. (1998). JW: Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma.
  18. (1995). Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res
  19. (2004). Kallioniemi OP: Highimpact of copy number on gene expression. Neoplasia
  20. (2005). L: Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacementbased whole-genome amplification. Electrophoresis
  21. (2002). Lasken RS: Comprehensive human genome amplification using multiple displacement amplification.
  22. (2001). Lasken RS: Rapid amplification of plasmid and phage DNA using Phi 29 DNA polymerase and multiply-primed rolling circle amplification. Genome Res
  23. (1995). Lichter P: Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer
  24. (2003). MP: Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. doi
  25. Multiple displacement amplification of genomic DNA.
  26. (1998). ON: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. doi
  27. (1999). Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum Pathol
  28. (1992). Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science
  29. (2003). PM: Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res
  30. (2004). Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Oncol doi
  31. (2004). Sellers WR: Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res
  32. (2002). Squire JA: Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med
  33. (2004). Squire JA: Use of whole genome amplification and comparative genomic hybridisation to detect chromosomal copy number alterations in cell line material and tumour tissue. Cytogenet Genome Res
  34. (2002). SS: Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis.
  35. (2004). T: Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
  36. (2005). The use of whole genome amplification in the study of human disease. Prog Biophys Mol Biol
  37. (2003). Vogel W: Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families.
  38. (2004). Zunino F: Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel. Biochem Pharmacol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.